Skye Bioscience, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
Skye Bioscience, Inc. (SKYE) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-03-20
- Skye Bioscience, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Skye Bioscience, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $4.46M.
- Skye Bioscience, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-20 |
| 2023-12-31 | $4.46M 10-K · filed 2025-03-20 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |